Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Relay Therapeutics Inc (NQ: RLAY ) 6.640 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Relay Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week September 15, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets Why Relay Therapeutics Plummeted by Nearly 14% Today September 11, 2024 Investors weren't happy with the company's latest effort at capital-raising. Via The Motley Fool Why Relay Therapeutics (RLAY) Stock Is Down 17% Today September 11, 2024 Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. Via Benzinga This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday September 11, 2024 Via Benzinga GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session September 11, 2024 Via Benzinga Expert Ratings For Relay Therapeutics August 07, 2024 Via Benzinga Expert Ratings For Relay Therapeutics July 17, 2024 Via Benzinga Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket September 11, 2024 Via Benzinga Relay Therapeutics Announces Pricing of Public Offering of Common Stock September 10, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market September 10, 2024 Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns... Via Benzinga AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th September 10, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday September 10, 2024 Via Benzinga Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone September 10, 2024 Via Benzinga Topics Stocks Exposures US Equities Relay Therapeutics Announces Proposed Public Offering of Common Stock September 09, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher September 09, 2024 Via Benzinga Exposures Fossil Fuels Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July September 09, 2024 Via Benzinga Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients September 09, 2024 Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... Via Benzinga Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday September 09, 2024 Via Benzinga US Stocks Higher; Dow Surges Over 200 Points September 09, 2024 Via Benzinga Topics Stocks Exposures US Equities Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival September 09, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024 September 06, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! September 05, 2024 The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... Via Talk Markets Topics Economy Exposures Economy Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week August 27, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. Via Talk Markets RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024 August 06, 2024 RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights August 06, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024 July 30, 2024 From Relay Therapeutics, Inc. Via GlobeNewswire AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD July 30, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. Via Talk Markets These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why July 24, 2024 This article identifies the Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD July 18, 2024 To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... Via Talk Markets Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD July 14, 2024 The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... Via Talk Markets < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.